Xtent tightens belt; axes jobs
This article was originally published in Clinica
Coronary drug-eluting stent developer Xtent said it is cutting its workforce by a third in a bid to pare down its expenses. In an SEC filing, the Menlo Park, California firm disclosed that it is eliminating 47 full-time jobs and 26 temporary positions, bringing the total number of staff down from around 200 to 135. The job cuts are expected to be completed this month.